FNY Investment Advisers LLC Acquires 42,298 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

FNY Investment Advisers LLC raised its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 125.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 75,966 shares of the company’s stock after acquiring an additional 42,298 shares during the period. FNY Investment Advisers LLC owned about 0.13% of Ginkgo Bioworks worth $745,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Algert Global LLC bought a new position in shares of Ginkgo Bioworks during the 2nd quarter worth approximately $36,000. Wellington Wealth Strategies LLC. acquired a new position in shares of Ginkgo Bioworks in the 2nd quarter worth approximately $41,000. Thoroughbred Financial Services LLC acquired a new stake in Ginkgo Bioworks during the 2nd quarter valued at $70,000. Benjamin F. Edwards & Company Inc. boosted its stake in Ginkgo Bioworks by 1,606.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company’s stock worth $79,000 after purchasing an additional 221,078 shares in the last quarter. Finally, Mackenzie Financial Corp bought a new stake in shares of Ginkgo Bioworks during the second quarter worth $251,000. 78.63% of the stock is owned by institutional investors.

Ginkgo Bioworks Stock Performance

Shares of DNA stock opened at $8.83 on Tuesday. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.26 and a 12 month high of $64.40. The firm has a market capitalization of $507.54 million, a price-to-earnings ratio of -0.68 and a beta of 1.09. The stock has a 50-day moving average price of $9.18.

Analyst Ratings Changes

Separately, TD Cowen raised their price objective on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, September 20th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $4.58.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.